NCT07194915 (TORPIDS-3) is a clinical trial in Pleural Infection, sponsored by University of Oxford.

Who is sponsoring NCT07194915?

NCT07194915 is sponsored by University of Oxford.

What condition does NCT07194915 study?

NCT07194915 studies Pleural Infection.

Is NCT07194915 still recruiting?

NCT07194915 is currently active, enrolled. Last updated 26 September 2025.

Last reviewed 2025-09-26 · How we verify

NCT07194915: TORPIDS-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection (TORPIDS-3)

Active, enrolled Last updated 26 September 2025

What this trial tests

trial in Pleural Infection in 326 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 January 2024

Primary endpoint
31 August 2025

1 October 2025

Quick facts

Lead sponsor	University of Oxford
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	326
Start date	9 January 2024
Primary completion	31 August 2025
Estimated completion	1 October 2025
Sites	1 location across United Kingdom

Conditions studied

Pleural Infection — all drugs for Pleural Infection →

Sponsor

University of Oxford

Who can join

18 and older, any sex, with Pleural Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pleural infection is a severe and complicated disease which is associated with significant morbidity and mortality. People with pleural infection show diverse levels of neutrophil degranulation activity. The investigators examined the biological role of pleural fluid neutrophil extracellular traps in patients with pleural infection. TORPIDS-3 is an observational, International multicohort study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pleural Infection

Currently open trials in the same condition.

NCT05766124 — Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE) · Phase 2, PHASE3 · recruiting
NCT06427538 — Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07194915 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 26 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07194915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing